Evaluation of Synthetic Cytochrome P-Mimetic Metalloporphyrins To Facilitate "Biomimetic" Biotransformation of a Series of MGlu Allosteric Ligands

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2019 Aug 29

PMID 31460402

Authors

Christopher C Presley

Charles K Perry

Elizabeth S Childress

Matthew J Mulder

Vincent B Luscombe

Alice L Rodriguez

Colleen M Niswender

P Jeffrey Conn

Craig W Lindsley

Affiliations

Soon will be listed here.

Abstract

Allosteric ligands within a given chemotype can have the propensity to display a wide range of pharmacology, as well as unexpected changes in GPCR subtype selectivity, typically mediated by single-atom modifications to the ligand. Due to the unexpected nature of these "molecular switches", chemotypes with this property are typically abandoned in lead optimization. Recently, we have found that in vivo oxidative metabolism by CYPs can also engender molecular switches within allosteric ligands, changing the mode of pharmacology and leading to unwanted toxicity. We required a higher-throughput approach to assess in vivo metabolic molecular switches, and we turned to a "synthetic liver", a 96 well kit of biomimetic catalysts (e.g., metalloporphyrins) to rapidly survey a broad panel of synthetic CYPs' ability to oxidize/"metabolize" an mGlu PAM (VU0403602) known to undergo an in vivo CYP-mediated molecular switch. While the synthetic CYPs did generate a number of oxidative "metabolites" at known "hot spots", several of which proved to be pure mGlu PAMs comparable in potency to the parent, the known CYP-mediated in vivo ago-PAM metabolite, namely, VU0453103, was not formed. Thus, this technology platform has potential to identify hot spots for oxidative metabolism and produce active metabolites of small-molecule ligands in a high-throughput, scalable manner.

References

Arienti K, Brunmark A, Axe F, McClure K, Lee A, Blevitt J . Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005; 48(6):1873-85. DOI: 10.1021/jm0495935. View

Sharma S, Kedrowski J, Rook J, Smith R, Jones C, Rodriguez A . Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. J Med Chem. 2009; 52(14):4103-6. PMC: 3192011. DOI: 10.1021/jm900654c. View

Rodriguez A, Grier M, Jones C, Herman E, Kane A, Smith R . Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010; 78(6):1105-23. PMC: 2993468. DOI: 10.1124/mol.110.067207. View

Schann S, Mayer S, Franchet C, Frauli M, Steinberg E, Thomas M . Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. J Med Chem. 2010; 53(24):8775-9. DOI: 10.1021/jm101069m. View

Wood M, Hopkins C, Brogan J, Conn P, Lindsley C . "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry. 2011; 50(13):2403-10. PMC: 3792571. DOI: 10.1021/bi200129s. View

Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S . Action of molecular switches in GPCRs--theoretical and experimental studies. Curr Med Chem. 2012; 19(8):1090-109. PMC: 3343417. DOI: 10.2174/092986712799320556. View

Sheffler D, Wenthur C, Bruner J, Carrington S, Vinson P, Gogi K . Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg Med Chem Lett. 2012; 22(12):3921-5. PMC: 3365510. DOI: 10.1016/j.bmcl.2012.04.112. View

Mohr K, Schmitz J, Schrage R, Trankle C, Holzgrabe U . Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl. 2012; 52(2):508-16. DOI: 10.1002/anie.201205315. View

Sheng W, Jiang Q, Luo W, Guo C . Oxidative rearrangement of internal alkynes to give one-carbon-shorter ketones via manganese porphyrins catalysis. J Org Chem. 2013; 78(11):5691-3. DOI: 10.1021/jo400209p. View

10.

Bridges T, Rook J, Noetzel M, Morrison R, Zhou Y, Gogliotti R . Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Drug Metab Dispos. 2013; 41(9):1703-14. PMC: 3876804. DOI: 10.1124/dmd.113.052084. View

11.

Engers D, Lindsley C . Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. Drug Discov Today Technol. 2013; 10(2):e269-76. PMC: 3779342. DOI: 10.1016/j.ddtec.2012.10.007. View

12.

Wenthur C, Gentry P, Mathews T, Lindsley C . Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol. 2013; 54:165-84. PMC: 4063350. DOI: 10.1146/annurev-pharmtox-010611-134525. View

13.

Cho H, Garcia-Barrantes P, Brogan J, Hopkins C, Niswender C, Rodriguez A . Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. ACS Chem Biol. 2014; 9(10):2334-46. PMC: 4201332. DOI: 10.1021/cb500560h. View

14.

Conn P, Lindsley C, Meiler J, Niswender C . Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014; 13(9):692-708. PMC: 4208620. DOI: 10.1038/nrd4308. View

15.

Lindsley C . 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites. J Med Chem. 2014; 57(18):7485-98. PMC: 4174999. DOI: 10.1021/jm5011786. View

16.

Lindsley C, Emmitte K, Hopkins C, Bridges T, Gregory K, Niswender C . Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chem Rev. 2016; 116(11):6707-41. PMC: 4988345. DOI: 10.1021/acs.chemrev.5b00656. View